CNBC's Jim Cramer explains why he is watching shares of Celgene.» Read More
It's time for the Lightning Round. Cramer makes the call on viewer favorites.
When shares tumble sharply in a single session, you can be sure Jim Cramer wants to know what’s going on.
Mad Money host Jim Cramer discusses how PepsiCo has outrun its peer companies, and shares his view of Puma Biotechnology, which rocketed 295 percent higher today.
Customers love their food. But the CFO says there's little appetite for a stock split.
If you have a penchant for quizzes and such, Jim Cramer thinks this question could lead you to a solid stock idea.
Cramer often says that if you do homework, you can prosper by holding a relatively small number of stocks.
The Fast Money traders share their final trades of the day.
Bob Peck of SunTrust Robinson Humphrey, share three highlights from Facebook's earnings call.
The Fast Money traders take a look at today's biggest market movers.
Rounding up the comments out of Facebook's earnings conference call, with CNBC's Julia Boorstin, and Bob Peck of SunTrust Robinson Humphrey. CEO Mark Zuckerberg says there "still so much room to grow."
What to expect from Facebook's earnings conference call, with Bob Peck of SunTrust Robinson Humphrey.
The "Fast Money" traders debate the health of Facebook's quarterly earnings.
Facebook reported Q2 EPS of $0.42 ex-items on revenue of $2.91 billion. Martin Pyykkonen, Rosenblatt Securities; Colleen Taylor, TechCrunch reporter; Nicholas Carlson, Business Insider deputy editor; and Todd Schoenberger, J. Streicher Asset Management, discuss hesitance in the stock.
Bruce Jenkyn-Jones, head of listed equities at Impax Asset Management, says geopolitical events have shown the need for energy diversification. He selects his top "green" picks.
Results of a clinical trial of a breast cancer drug could make this company a takeover target, too, says CNBC's Jim Cramer.
CNBC's Jim Cramer says he is watching shares of Xilinx and explains why the credibility of the company is in question.
Jim Cramer explains what to watch ahead of the open, including Puma Biotechnology. Cramer says the stock could quadruple due to the results of a new drug trial.
Cramer thinks now is a good time to look at companies that have rallied post quarter, and then determine which could have more upside.
Had you followed Cramer into this stock, you’d be looking at upside. Serious upside.
“They are making statement about what people want to eat and, as a result, what investors should want to buy,” said Cramer.